Copenhagen‑based Genmab will acquire Dutch biotech Merus in an all‑cash transaction valued at DKK 51 billion (€6.8 billion), aiming to expand and diversify revenues and accelerate growth into the next decade. The deal, unanimously approved by both boards, will be executed via a tender offer and is expected to close in early Q1 2026, pending regulatory and shareholder approvals.
Deal terms and timeline: DKK 51bn and early‑2026 closing
Genmab plans to launch a tender offer for 100% of Merus shares, with the transaction unanimously recommended by both companies’ boards. The acquisition is designed to be EBITDA‑accretive by end‑2029, with financing through cash and new debt.
The companies expect completion in early 2026, subject to customary conditions, including a minimum acceptance threshold and regulatory clearances.
Pipeline boost: petosemtamab and late‑stage oncology
At the core of the deal is petosemtamab, Merus’ late‑stage EGFR×LGR5 bispecific antibody for head and neck squamous cell carcinoma (HNSCC). The candidate holds two U.S. FDA Breakthrough Therapy Designations and is being tested in Phase 3 trials in first‑line and later‑line HNSCC.
If outcomes are positive and approvals follow, initial launch could occur in 2027. Genmab says the asset could be first‑ and best‑in‑class, complementing its existing antibody portfolio.
Strategy shift: from licensing to wholly owned revenues
The acquisition advances Genmab’s pivot toward a wholly owned model, reducing reliance on partnered royalties and broadening revenue streams across multiple oncology indications.
Management argues the transaction will sustain growth into the next decade, building on recent portfolio moves and positioning Genmab for multiple new drug launches by 2027.
Danish footprint, EU reach
Headquartered in Valby (Copenhagen), Genmab strengthens Denmark’s role in European biotech while deepening ties with the Netherlands’ oncology ecosystem through Merus’ operations in Utrecht. For readers tracking the Nordic and EU innovation space, the deal underscores the regional scale‑up capacity of late‑stage biopharma.
What to watch next: approvals, data and integration
Key milestones include Merus shareholder consent, competition and regulatory reviews, and interim Phase 3 readouts expected in 2026. Integration plans, commercialization strategy for petosemtamab, and deleveraging targets after closing will be closely watched by investors and patients alike.
